A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have found that tipifarnib showed promise in treating HNSCC tumors with mutations in the HRAS gene.

0

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have found that tipifarnib showed promise in treating HNSCC tumors with mutations in the HRAS gene.

UC San Diego Health reports, “ Treatment with tipifarnib had a multifaceted effect on the biology of HRAS-mutant HNSCC tumors, reducing oncogenic signaling and proliferation, while increasing apoptosis (cell death), blocking angiogenesis (development of new blood vessels in tumors), and driving squamous differentiation of tumors.”

The study has been published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy